Patients with classic and nonclassic CAH, predominantly those with classic 21-hydroxylase deficiency
Care Setting
Endocrinology clinics managing lifelong hormone replacement and monitoring cardiometabolic risk
Key Highlights
Classic CAH is associated with increased cardiometabolic risk including weight gain, insulin resistance, hypertension, endothelial dysfunction, early atherosclerosis, and left ventricular diastolic dysfunction.
Cardiometabolic complications are more consistently reported in classic CAH than in nonclassic CAH and relate to hormonal imbalances and treatment challenges.
Excess cardiovascular and metabolic morbidity in CAH is multifactorial, involving glucocorticoid overtreatment, imperfect hormone replacement, androgen excess, and adrenomedullary failure.
Guideline-Based Recommendations
Diagnosis
Use genotyping of CYP21A2 variants to confirm diagnosis, guide genetic counseling, and prenatal diagnosis.
Differentiate classic (salt-wasting and simple virilizing) and nonclassic CAH based on enzymatic activity and clinical presentation.
Consider ACTH stimulation testing in nonclassic CAH to assess cortisol response.
Management
Replace deficient hormones with glucocorticoids and mineralocorticoids as appropriate.
Aim to reduce ACTH secretion and normalize androgen excess while avoiding overtreatment.
Monitor and adjust therapy to balance hormone replacement and minimize cardiometabolic risks.
Monitoring & Follow-up
Regular assessment of weight, blood pressure, insulin sensitivity, and cardiovascular function.
Evaluate for early signs of endothelial dysfunction and atherosclerotic changes.
Monitor for left ventricular diastolic dysfunction and other cardiac abnormalities.
Risks
Risk of life-threatening salt-wasting crisis in salt-wasting CAH if untreated.
Potential for glucocorticoid overtreatment leading to metabolic complications.
Risk of androgen excess contributing to cardiometabolic abnormalities.
Patient & Prescribing Data
Adults and children with classic and nonclassic CAH due to 21-hydroxylase deficiency
Glucocorticoid therapy must be carefully balanced to replace deficient hormones and suppress excess androgens without causing overtreatment-related cardiometabolic complications.
Clinical Best Practices
Early diagnosis and lifelong hormonal substitution tailored to phenotype and genotype.
Use genotyping to inform prognosis and personalize treatment.
Regular cardiometabolic risk assessment and management integrated into routine care.
Avoid overtreatment with glucocorticoids to minimize metabolic and cardiovascular morbidity.
Consider future targeted studies to evaluate cardiometabolic effects of new therapies.
